PMLiVE5d
AstraZeneca’s Fasenra approved by EC to treat rare inflammatory disease EGPA
AstraZeneca’s Fasenra (benralizumab) has been approved by the European Commission (EC) to treat eosinophilic granulomatosis ...
PMLiVE6d
Countdown to an optimised drug launch: five determinants of success
The launch of a new pharmaceutical product depends on a host of determinants and it just takes one factor to send the launch ...
PMLiVE6d
EatMoreFruit announces launch of European PR Network
EatMoreFruit, a UK top 10 independent healthcare communication agency, today announced the launch of its European Network to ...
PMLiVE9d
Is your influenza clinical trial prepared for the upcoming flu season? Part 2
Around 86% of clinical trials do not meet patient recruitment goals, ultimately failing to improve patient outcomes and ...
PMLiVE9d
The secrets of the pharmaceutical launch A-team
Knowing this, it amazes me how many pharmaceutical organisations of all sizes are missing the mark on key areas of launch ...
PMLiVE12d
Merck acquires oncology spinout Modifi Biosciences in deal worth $1.3bn
Merck & Co – known as MSD outside the US and Canada – has acquired Yale University oncology spinout Modifi Biosciences in a deal worth $1.3bn. The agreement gives Merck access to preclinical compounds ...
PMLiVE18d
Merck’s Keytruda recommended by NICE to reduce risk of lung cancer recurrence
Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat resectable non-small cell ...
PMLiVE13d
Novartis’ Kisqali receives CHMP recommendation for early breast cancer patients
Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...
PMLiVE10d
AbbVie to expand neuroscience pipeline with $1.4bn Aliada Therapeutics acquisition
AbbVie has announced that it will be acquiring Aliada Therapeutics for $1.4bn, marking a notable boost to its neuroscience pipeline. The deal gives AbbVie access to Aliada’s therapies that use a novel ...
PMLiVE13d
J&J’s Darzalex regimen approved by EC for newly diagnosed multiple myeloma
Johnson & Johnson (J&J) has announced that a subcutaneous (SC) formulation of Darzalex (daratumumab) has been approved by the European Commission (EC) as part of a combination treatment for newly ...
PMLiVE10d
Johnson & Johnson’s Tremfya shows promise in ‘special site’ plaque psoriasis
Johnson & Johnson (J&J) has shared positive results from a late-stage study of its dual-acting IL-23 inhibitor Tremfya (guselkumab) in plaque psoriasis patients. The phase 3b SPECTREM trial has been ...
PMLiVE9d
Novartis’ Scemblix granted FDA accelerated approval in newly diagnosed CML
Novartis’ Scemblix (asciminib) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat a new subset of chronic myeloid leukaemia (CML) patients. The STAMP inhibitor ...